2013 American Society of Hematology Annual Meeting*

December 7-10, 2013; New Orleans, Louisiana
CCO’s Independent Conference Coverage of the 2013 American Society of Hematology annual meeting includes Capsule Summaries of key studies plus expert analyses of new clinical trial findings with downloadable highlights slidesets. Topics include chronic lymphocytic leukemia and other B-cell malignancies, chronic myeloid leukemia, myelodysplastic syndromes and acute leukemias, and multiple myeloma.

Chronic Lymphocytic Leukemia and Other B-Cell Malignancies

Capsules

High baseline sPD-L1 plasma levels predict shorter OS, independent of treatment with R-CHOP or R-HDT.

Released: December 11, 2013

In this phase II study, brentuximab appeared to be safe and well tolerated by elderly patients with HL who have limited tolerance to conventional therapies and poorer prognosis than younger patients.

Released: December 14, 2013

FCR yields higher rates of CR and MRD negativity, and longer PFS, in comparison to BR, but was associated with increased adverse events, in patients with untreated, active CLL without del(17p) and good physical fitness.

Released: December 13, 2013

In this phase III trial, the addition of ofatumumab to chlorambucil in patients 65 years of age or older who are not suitable for fludarabine improved PFS, response rates, and extended the treatment-free period by more than 1 year compared with chlorambucil alone.

Released: December 14, 2013

The obinutuzumab combination improved survival and clinical response rate in patients with previously untreated CLL with comorbidities vs the rituximab combination or chlorambucil alone with similar safety profiles.

Released: December 10, 2013

In a phase II trial, a rituximab/ibrutinib regimen was well tolerated and showed high activity as measured by ORR and lymphocyte reduction.

Released: December 14, 2013

In this phase II trial, efficacy of idelalisib was independent of previous treatment history, histologic subtype, or degree of refractory disease.

Released: December 10, 2013

In this phase II study, high rates of PFS, EFS, and OS were seen in patients with DLBCL, regardless of cell of origin.

Released: December 15, 2013

Response rates were similar in high-risk patients with del(17p) and fludarabine resistance.

Released: December 13, 2013

In interim results of a phase III study, idelalisib plus rituximab improved PFS and OS vs rituximab plus placebo in a heavily pretreated population, including patients with unfavorable genetics, with an acceptable safety profile.

Released: December 13, 2013
Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
Celgene Corporation
Genentech BioOncology
Gilead Sciences
Takeda Oncology
Novartis Oncology
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?